Nivolumab+AVD in Advanced-Stage Classic Hodgkin’s Lymphoma
N+AVD resulted in longer progression-free survival than BV+AVD in adolescents and adults with stage III or IV advanced-stage classic Hodgkin's lymphoma and had a better side-effect profile. (Funded by the National Cancer Institute of the National Institutes of Health and others; S1826 ClinicalTrials.gov number, NCT03907488.).
Authors
- Susan K. Parsons (ORCID: https://orcid.org/0000-0003-0282-6490)
- Craig H. Moskowitz (ORCID: https://orcid.org/0000-0002-9189-3152)
- Louis S. Constine (ORCID: https://orcid.org/0000-0003-0742-1740)
- Sonali M. Smith (ORCID: https://orcid.org/0000-0002-9893-4949)
- Alexandra E. Kovach (ORCID: https://orcid.org/0000-0002-6742-6749)
- David Hodgson (ORCID: https://orcid.org/0000-0003-4687-4582)
- Christopher J. Forlenza (ORCID: https://orcid.org/0000-0003-2246-1206)
- Pankaj Kumar (ORCID: https://orcid.org/0000-0003-3299-7995)
- Margaret A. Shipp (ORCID: https://orcid.org/0000-0002-3949-6897)
- Boyu Hu (ORCID: https://orcid.org/0000-0001-9848-9497)
- Anamarija M. Perry (ORCID: https://orcid.org/0000-0002-5700-2141)
- Anca A. Prica (ORCID: https://orcid.org/0000-0001-5621-9261)
- Namita Sharma (ORCID: https://orcid.org/0000-0002-6429-0372)
- Joo Y. Song (ORCID: https://orcid.org/0000-0003-3497-2513)
- Alex Francisco Herrera (ORCID: https://orcid.org/0000-0002-9665-7415)
- Andrew Doan (ORCID: https://orcid.org/0000-0002-8362-549X)
- Brian T. Hess (ORCID: https://orcid.org/0000-0003-0176-2050)
- Ryan Jacobs (ORCID: https://orcid.org/0000-0001-7814-7959)
- Sharon M. Castellino (ORCID: https://orcid.org/0000-0001-8367-2002)
- John P. Leonard (ORCID: https://orcid.org/0000-0002-5083-1115)
- Jonathan W. Friedberg (ORCID: https://orcid.org/0000-0002-1420-5563)
- Sairah Ahmed (ORCID: https://orcid.org/0000-0001-7302-8299)
- Michael LeBlanc (ORCID: https://orcid.org/0000-0001-7192-2860)
- Adam J. Lamble (ORCID: https://orcid.org/0000-0002-7781-2918)
- Joseph M. Tuscano (ORCID: https://orcid.org/0000-0002-0522-1406)
- Hayder Saeed (ORCID: https://orcid.org/0000-0001-5295-6088)
- Pallawi Torka (ORCID: https://orcid.org/0000-0002-1681-5883)
- Richard F. Little (ORCID: https://orcid.org/0000-0002-4091-1699)
- Gaurav Goyal (ORCID: https://orcid.org/0000-0001-6148-5177)
- Kristie A. Blum (ORCID: https://orcid.org/0000-0003-4229-2569)
- Michael Crump (ORCID: https://orcid.org/0000-0002-2230-8538)
- Matthew Mei (ORCID: https://orcid.org/0000-0002-1109-6955)
- Andrew M. Evens (ORCID: https://orcid.org/0000-0002-6900-1824)
- Angela Punnett (ORCID: https://orcid.org/0000-0003-4541-0823)
- Brad S. Kahl (ORCID: https://orcid.org/0000-0003-0459-6609)
- Kelly Davison (ORCID: https://orcid.org/0000-0001-5159-3916)
- Avina K. Singh
- Nancy L. Bartlett (ORCID: https://orcid.org/0000-0001-8470-394X)
- Brett T. Brinker (ORCID: https://orcid.org/0000-0003-2139-7820)
- Kara M. Kelly (ORCID: https://orcid.org/0000-0003-1473-3937)
- Sarah C. Rutherford (ORCID: https://orcid.org/0000-0002-1064-7727)
- Hongli Li (ORCID: https://orcid.org/0009-0000-9450-387X)
- Supreet Kaur (ORCID: https://orcid.org/0000-0002-1361-922X)
- S. Chowdhury (ORCID: https://orcid.org/0000-0003-1279-3442)
- Carla Casulo (ORCID: https://orcid.org/0000-0001-9993-5065)
- Hildy Dillon
- Lale Kostakoglu Shields
Institutions
- Cornell University (US)
- City of Hope (US)
Publication Details
- Journal
- New England Journal of Medicine
- Published
- 2024-10-16
- DOI
- https://doi.org/10.1056/nejmoa2405888
- Citations
- 165
- Primary Topic
- Lymphoma Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 69.70
Funders
- Bristol-Myers Squibb
- Leukemia and Lymphoma Society
- Seagen
- National Institutes of Health
- National Cancer Institute